What is Inhibrx Biosciences, Inc.'s operating cash flow?

Inhibrx Biosciences, Inc. (INBX) reported operating cash flow of -$38.03M in Q1 2026.

How has Inhibrx Biosciences, Inc.'s operating cash flow changed year-over-year?

Inhibrx Biosciences, Inc.'s operating cash flow decreased by 5.9% year-over-year, from -$35.9M to -$38.03M.

What does operating cash flow mean?

Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Inhibrx Biosciences, Inc. INBX Operating Cash Flow

Operating Cash Flow at other companies

PfizerPFE

$2.62B+12.0%

Rogers CorporationROG

$5.8M-50.4%

Merck & Co.MRK

$3.92B+56.7%

Gilead SciencesGILD

$2.54B+44.8%

Nuvation BioNUVB

$5.07M+112%

ArriVent BioPharma, Inc.AVBP

-$41.89M+38.4%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+547%

Enterprise value$1.42B+1,236%

P/S1,075.6×-281×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s operating cash flow?: Inhibrx Biosciences, Inc. (INBX) reported operating cash flow of -$38.03M in Q1 2026.
How has Inhibrx Biosciences, Inc.'s operating cash flow changed year-over-year?: Inhibrx Biosciences, Inc.'s operating cash flow decreased by 5.9% year-over-year, from -$35.9M to -$38.03M.
What does operating cash flow mean?: Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.